TB-500 Peptide

TB-500, also known as synthetic Thymosin Beta-4 (Tβ4), is a 43–amino acid peptide modeled after the naturally occurring protein encoded by the TMSB4X gene. It is found in high concentrations in platelets and wound fluid and is studied for its potential roles in tissue repair, angiogenesis, and inflammation modulation.(1)

Overview

TB-500 contains an active region (LKKTETQ sequence) believed to be involved in actin binding, cell migration, and wound healing.(2)

It is thought to interact with actin by binding to globular actin (G-actin), influencing cytoskeletal structure and cell movement. This may impact processes such as:

• Tissue repair and regeneration

• Angiogenesis (new blood vessel formation)

• Cellular migration and remodeling

TB-500 has also been detected extracellularly, where it may influence vascular cell activity and angiogenesis, possibly through interactions with cell-surface enzymes.(11)(12)

Chemical Makeup

Molecular Formula: C₂₁₂H₃₅₀N₅₆O₇₈SMolecular Weight: 4963 g/molOther Known Titles: Thymosin Beta 4

Research and Clinical Studies

TB-500 Peptide and Inflammation

Research suggests TB-500 may exert anti-inflammatory effects through regulation of microRNA-146a, which may suppress inflammatory signaling pathways involving IRAK1 and TRAF6.(4)

TB-500 Peptide and Acute Wounds

Animal studies indicate TB-500 may accelerate wound healing:

• ~41% increase in re-epithelialization after 4 days

• Greater wound contraction compared to controls

• Increased collagen deposition and angiogenesis(5)

These findings suggest a role in enhancing early-stage tissue repair.

TB-500 Peptide and Chronic Wounds

Studies in various animal models (including diabetic and aged models) suggest TB-500 may accelerate healing regardless of underlying conditions.

Clinical investigations in ulcer models reported:

• Faster healing times, potentially by up to one month(6)

TB-500 Peptide and Heart Cells

Research suggests TB-500 may influence cardiac repair and function:

• Reduced right ventricular hypertrophy in experimental models

• Increased cardiomyocyte survival under stress

• Enhanced angiogenesis and cardiac cell migration

Potential mechanisms involve pathways such as ILK and Akt, which are associated with cell survival and regeneration.(7)(9)

TB-500 and Hair Follicle Growth

In 2003, studies were carried out on mice to examine the potential of TB-500 in hair growth. Under the influence of the TB-500 peptide, it was reported by the researchers that, via histological examination of the mouse skin cells, the peptide appeared to increase the number of hair shafts and hair follicles, thereby inducing hair growth. Upon real-time PCR and western blotting techniques, changes in the expression of m-RNA cells were observed between the TB500 and control mice. The m-RNA and protein levels were reported elevated in TB-500 mice, which might have significantly induced hair growth.⁽¹⁰⁾

TB-500 and Blood Vessel Formation

It is hypothesized that TB-500 might influence angiogenesis via several molecular interactions. This is based on studies involving TB-500 overexpression lentiviral vector in transfecting umbilical vein endothelial cells (HUVEC) and murine critical limb ischemia (CLI) models.⁽¹³⁾ Researchers have also employed inhibitors such as DAPT, targeting the Notch pathway, and BMS, affecting the NF-κB pathway, in both HUVEC and murine CLI experiments to probe the intricate biological processes involved. The potential of TB-500 on angiogenesis and cellular migration were evaluated using MTT assays to measure cell viability, alongside tube formation and wound healing assays to assess angiogenic and migratory capabilities, respectively. Additionally, a variety of molecular methodologies were utilized, including Western blotting, reverse transcription, quantitative PCR, immunofluorescence, and immunohistochemistry. These techniques were instrumental in investigating the expression levels of angiogenesis-associated markers and elements related to the Notch/NF-κB pathways. Preliminary findings indicate that TB-500 might enhance not only the viability, angiogenesis, and migration of HUVEC but could also elevate the expression of angiopoietin-2 (Ang2), TEK receptor tyrosine kinase 2 (tie2), vascular endothelial growth factor A (VEGFA), NOTCH1 intracellular domain (N1ICD), Notch receptor 3 (Notch3), NF-κB, and phosphorylated (p)-p65 in these cells. In the muscle tissues of murine CLI models, similar increases in the expression of CD31, α-smooth muscle actin (α-SMA), Ang2, tie2, VEGFA, N1ICD, and p-p65 were observed, suggesting a regulatory potential of TB-500 on these molecular targets. Interestingly, the application of DAPT and BMS in these studies seemed to counteract the actions of TB-500, potentially indicating that the mechanisms of action of TB-500 in promoting angiogenesis might be mediated through its interactions with the Notch and NF-κB pathways. Moreover, the apparent reversal of the actions of DAPT and BMS by TB-500 could underscore its role in modulating these pathways, supporting the proposition of its regulatory functions in angiogenesis. Researchers have noted that these observations might imply a role for Tβ4 in promoting angiogenesis through regulation of these critical pathways.

TB-500 and Corneal Tissues

Studies have posited that TB-500 may modulate cytokine production and thus accelerate healing in corneal wound models.⁽¹⁴⁾ Following injury, there is some indication that TB-500 could promote increased expression of IL-1β and IL-6 mRNA in the corneas of murine models. Moreover, TB-500 experimentation after alkali injury might lead to a decrease in the expression of chemoattractants such as MIP-2 and KC for polymorphonuclear neutrophils (PMNs) in mouse corneas, potentially resulting in diminished PMN infiltration. Concerning the inflammatory signaling pathways in the cornea, it is speculated that TB-500 may influence NFκB pathways, possibly exerting anti-inflammatory actions. TB-500 is also theorized to possess anti-apoptotic attributes. An overexpression of TB-500 in cellular models is observed to potentially increase growth rates, diminish basal apoptosis, and confer resistance to factors that induce cell death. In corneal epithelial cells, TB-500 could potentially inhibit apoptosis by blocking caspases and curtailing the release of the pro-apoptotic protein bcl-2 from mitochondria. The mechanism of TB-500’s anti-apoptotic action might include reducing the initiation signals of early cell death and activating the survival kinase Akt via complex interactions with PINCH and integrin-linked kinase. It is conceivable that TB-500’s anti-apoptotic influence operates through several molecular pathways. Nonetheless, it is crucial to acknowledge that these mechanisms remain conjectural and warrant further empirical investigation to be substantiated.